Priabprat Jansem

Priabprat Jansem

Auto-generated profile, based on publicly available information

Priabprat Jansem

Department of Psychiatry, Faculty of Medicine, Prince of Songkla University , Songkhla

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Neuroscience & Biobehavioral Reviews
Verified
Journal Article
Closed access
KJKetsupar Jirakran
Ketsupar Jirakran
Abbas F. AlmullaAbbas F. Almulla
Abbas F. Almulla
TJThapanee Jaipinta
Thapanee Jaipinta
AVAsara Vasupanrajit
Asara Vasupanrajit
PJPriabprat Jansem
Priabprat Jansem
MMMichael Maes
Michael Maes

22 September 2025 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
PNPannathorn Nakaphan
Pannathorn Nakaphan
PPPatavee Pajareya
Patavee Pajareya
PJPriabprat Jansem
Priabprat Jansem
SPSomkiat Phutinart
Somkiat Phutinart
NCNattanicha Chaisrimaneepan
Nattanicha Chaisrimaneepan
NSNoppachai Siranart
Noppachai Siranart

13 June 2025 in Indian Pacing and Electrophysiology Journal
Verified
Journal Article
Open access
PPPatavee Pajareya
Patavee Pajareya
SPSomkiat Phutinart
Somkiat Phutinart
NSNoppachai Siranart
Noppachai Siranart
SPSuwit Paksin
Suwit Paksin
PJPriabprat Jansem
Priabprat Jansem
NTNithi Tokavanich
Nithi Tokavanich
Cryptogenic stroke (CS) presents challenges in management and increases risk of stroke recurrence. The clinical relevance of atrial fibrillation detected after stroke (AFDAS) remains equivocal. Our study was conducted in a meta-analysis design, including all observational studies and utilizing random-effects model. The objectives were to explore the association between predictors and AFDAS incidence, and clinical differences between AF and non-AF patients following CS. This meta-analysis included 59 studies with 18,683 patients with CS. AFDAS incidence was 20.8%. In univariable analysis, significant predictors of AFDAS were age >75 years(OR 6.94, 95%CI: 3.12-15.43, I2=0.0%) and hypertension(OR 2.16, 95%CI: 1.28-3.63, I2=0.0%). In comparison to non-AF group, individuals with AF showed significantly higher levels of left atrial volume index(MD 7.50 mL/m2, 95%CI: 6.20-8.80, I2=0.0%), left atrial diameter(MD 0.17 cm, 95%CI: 0.02-0.32, I2=48.6%), D-dimer (MD 0.20 mg/L, 95%CI: 0.05-0.36, I2=0%), CHA2DS2VASc score(MD 0.76 point, 95%CI: 0.53-0.98, I2=64.2%), and P-wave duration(MD 9.49 ms, 95%CI: 0.75-18.23, I2=30.4%). Significantly lower levels were observed in left atrial contractile strain(MD -5.68%, 95%CI: -7.45 - -3.91, I2=58.0%) and left atrial reservoir strain(MD -9.05%, 95%CI: -12.2 - -5.91, I2=71.9%). The mean time from CS to AF detection was 162 days and from cardiac monitoring to AF detection was 49 days. Our study highlighted the potential link between certain comorbidities and demonstrated the delay in AF detection following CS. The significant parameters identified should be considered as new recommendations to the guideline for extended cardiac monitoring in CS patients. It is time to change the level of surveillance in this population.

8 November 2025 in Modern Rheumatology
Verified
Journal Article
Closed access
PNPannathorn Nakaphan
Pannathorn Nakaphan
SPSomkiat Phutinart
Somkiat Phutinart
PPPatavee Pajareya
Patavee Pajareya
PJPriabprat Jansem
Priabprat Jansem
SSSireenada Sattawatthamrong
Sireenada Sattawatthamrong
NSNoppachai Siranart
Noppachai Siranart
Objective: Calcium pyrophosphate deposition disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an interleukin-1 inhibitor, is a promising alternative. We aimed to evaluate the efficacy and safety of anakinra in acute CPPD flares. Methods: We systematically searched studies from MEDLINE, EMBASE, and the Cochrane Database up until August 2024. The primary outcome was a positive treatment response between Day 3 and Day 5 after anakinra initiation. Secondary outcomes included changes in pain ratings assessed by the visual analogue scales (VAS), C-reactive protein (CRP) levels, tender joint counts (TJCs), swollen joint counts (SJCs), and steroid usage. Results: Six studies were included in our meta-analysis: five observational studies and one randomized controlled trial. A total of 84 patients were included in our analysis. Subjective physician assessments of clinical response were reported in all studies with a combined positive treatment response rate of 76% (95% CI: 61–86, I2 = 0%). Our pooled analysis also showed a significant reduction of VAS scores by 48.12 mm (95% CI: 53.21–43.03, I2 = 0%) and CRP levels by 62.09 mg/L (95% CI: 97.74–26.44, I2 = 77%) from baseline. Reductions of TJC and SJC were also demonstrated: 4.86 (95% CI: 5.48–4.23, I2 = 0%) and 3.65 (95% CI: −12.53 to 5.22, I2 = 54%), respectively. Adverse reactions included injection site reaction, rash, bacterial pneumonitis, and neutropenia. Conclusions: Anakinra is a promising alternative treatment for patients with acute CPPD flare as it showed desirable clinical responses and a favourable safety profile.

12 March 2024 in European journal of pain
Verified
Journal Article
Closed access
PJPriabprat Jansem
Priabprat Jansem
NWNattapat Watanapa
Nattapat Watanapa
STSekh Thanprasertsuk
Sekh Thanprasertsuk
WRWanakorn Rattanawong
Wanakorn Rattanawong
Thanakit PongpitakmethaThanakit Pongpitakmetha
Thanakit Pongpitakmetha
PAPrakit Anukoolwittaya
Prakit Anukoolwittaya

22 September 2024 in medRxiv
Verified
Preprint
Open access
PDF file
KJKetsupar Jirakran
Ketsupar Jirakran
Abbas F. AlmullaAbbas F. Almulla
Abbas F. Almulla
TJThapanee Jaipinta
Thapanee Jaipinta
AVAsara Vasupanrajit
Asara Vasupanrajit
PJPriabprat Jansem
Priabprat Jansem
MMMichael Maes
Michael Maes
Background Major depressive disorder (MDD) and bipolar disorder (BD) often coexist with metabolic syndrome. Both are linked to increased atherogenicity and a higher risk of cardiovascular diseases. Objectives This meta-analysis seeks to evaluate the relationship between atherogenic indices and mood disorders (MDD/BD), while identifying the most effective atherogenic biomarkers for mood disorders. Methods This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We searched electronic databases, including PubMed, Google Scholar, and Web of Science, for articles published up to August 1, 2024. Results In this meta-analysis, 85 eligible studies (14 on BD and 71 on MDD) were included, covering 70,856 participants: 18,738 patients and 52,118 healthy controls. Patients with mood disorders showed significant increases (p < 0.001) in the Castelli Risk Index 2 (CRI2), Atherogenic Index of Plasma (AIP), and (triglyceride or TG + low-density lipoprotein + very low-density lipoprotein)/(high-density lipoprotein cholesterol or HDL + Apolipoprotein A or ApoA) ratio, but not CRI1 and ApoB/ApoA ratio. Significant lower HDL and lecithin: cholesterol acyltransferase activity, and higher TG levels were observed in mood disordered patients compared with controls. There were no significant differences between MDD and BD patients. Most included studies lacked the most essential information on the inclusion and exclusion of important confounders. Conclusions AIP is the most effective atherogenicity index for mood disorders. Regular lipid profiling and metabolic syndrome screening are crucial in mood disorders. Early intervention with lipid-lowering therapies is recommended to prevent the worsening of atherogenicity and disease progression.